Abstract This is a Brighton Collaboration Case Definition of the term “Vaccine Associated
Enhanced Disease” to be utilized in the evaluation of adverse events following …

RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has
limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding …

Human respiratory syncytial virus (RSV) was first isolated in 1956 from a laboratory
chimpanzee with upper respiratory tract disease (for general reviews, see references 21, 57 …

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. A formalin-
inactivated RSV vaccine was used to immunize children and elicited nonprotective …

CD8 T cells respond to viral infections but also participate in defense against bacterial and
protozoal infections. In the last few years, as new methods to accurately quantify and …

Rationale: Respiratory syncytial virus (RSV) is the leading cause of childhood lower
respiratory infection, yet viable therapies are lacking. Two major challenges have stalled …

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in
infants and young children. Administration of a formalin inactivated vaccine against RSV to …

TNF antagonists are effective treatments for rheumatoid arthritis and Crohn′ s disease, and
have been tried with variable success in other diseases caused by immune damage. To test …

Respiratory syncytial virus (RSV) is one of the commonest and most troublesome viruses of
infancy. It causes most cases of bronchiolitis, which is associated with wheezing in later …

Respiratory synctial virus (RSV) infections are a common and concerning conundrum. This
ubiquitous agent is the major respiratory pathogen of young children, with life‐threatening …